Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the general description of pramipexole as a dopamine agonist with mechanisms relevant to Parkinson’s disease and RLS is partially supported by the provided label excerpts. The majority of claims about impulse control disorders, including boxed warning existence/content, specific behavioral subtypes, quantitative incidence/placebo comparisons, dose/demographic/timing risk modifiers, and mechanistic/genetic explanations are not supported by the supplied label sections.
Category Scores
Accurate Statements
Mirapex (pramipexole) is a dopamine agonist used for Parkinson's disease.
Mechanism-of-action excerpt describes pramipexole as a dopamine agonist and discusses its relatedness to stimulating dopamine receptors in the striatum for Parkinson’s disease (CLINICAL PHARMACOLOGY – Mechanism of Action).
Mirapex (pramipexole) is used for restless legs syndrome.
Mechanism-of-action excerpt discusses Mirapex (pramipexole) in the context of treating RLS (CLINICAL PHARMACOLOGY – Mechanism of Action).
Unsupported Statements
Mirapex is linked to impulse control disorders including pathological gambling.
Impulse control disorders/behavioral effects and any related boxed warning content are not present in the provided label excerpts.
Mirapex is linked to impulse control disorders including hypersexuality.
Impulse control disorders and hypersexuality are not present in the provided label excerpts.
Mirapex is linked to impulse control disorders including compulsive shopping.
Impulse control disorders and compulsive shopping are not present in the provided label excerpts.
Mirapex is linked to impulse control disorders including binge eating.
Impulse control disorders and binge eating are not present in the provided label excerpts.
The FDA requires a boxed warning on Mirapex for risks of impulse control disorders including pathological gambling, hypersexuality, compulsive shopping, and binge eating.
No boxed warning text is included in the provided label excerpts, so boxed warning existence/content cannot be verified.
Up to 13% of patients experienced such behaviors with Mirapex.
No quantitative incidence for these behaviors is included in the provided label excerpts.
The rate of such behaviors with Mirapex was 2-3 times higher than placebo.
No placebo comparative rates for these behaviors are included in the provided label excerpts.
In studies, impulse control issues affected 7-17% of Mirapex users.
No study incidence range for impulse control issues is included in the provided label excerpts.
In studies, impulse control issues affected 4% of placebo users.
No placebo incidence for impulse control issues is included in the provided label excerpts.
Risk of impulse control disorders increases with higher doses of Mirapex (over 3 mg/day).
No dose-threshold relationship for impulse control disorders is included in the provided label excerpts.
Risk of impulse control disorders is higher in younger patients.
No age-specific risk statements for impulse control disorders are included in the provided label excerpts.
Risk of impulse control disorders is higher in men.
No sex-specific risk statements for impulse control disorders are included in the provided label excerpts.
Symptoms of impulse control disorders often start within months of starting Mirapex.
No onset timing information for impulse control disorder symptoms is included in the provided label excerpts.
Impulse control disorder symptoms can emerge anytime during Mirapex treatment.
No statements about anytime emergence of impulse control disorder symptoms are included in the provided label excerpts.
Beyond gambling, patients report hypersexuality (increased sexual urges or risky behavior) with Mirapex.
No label excerpt provided describing hypersexuality reports associated with Mirapex.
Beyond gambling, patients report compulsive buying with Mirapex.
No label excerpt provided describing compulsive buying reports associated with Mirapex.
Beyond gambling, patients report binge eating with Mirapex.
No label excerpt provided describing binge eating reports associated with Mirapex.
Hypersexuality, compulsive buying, and binge eating resolve in most cases after dose reduction or stopping Mirapex.
No resolution outcome language for these behaviors after dose reduction/cessation is included in the provided label excerpts.
Some cases of these behaviors may persist even after dose reduction or stopping Mirapex.
No persistence language for these behaviors after dose reduction/cessation is included in the provided label excerpts.
Mirapex may trigger these behaviors by mimicking dopamine in the brain's reward pathways.
No label excerpt provided describing this specific mechanistic attribution for impulse control disorders.
Mirapex may overstimulate brain areas linked to impulse control.
No label excerpt provided describing overstimulation of impulse-control-related brain areas.
Genetic factors may increase vulnerability to impulse control disorders with Mirapex.
No label excerpt provided discussing genetic vulnerability for impulse control disorders.
Contradictions
Important Omissions
For the impulse control disorder/boxed warning topic, the response does not cite or reflect any FDA label language for boxed warning, warnings/precautions, adverse reactions, or clinical study incidence/timing/demographics because those label sections were not provided. Material label-specific details are therefore missing from substantiation.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response makes numerous safety-relevant claims (boxed warning existence/content, risk modifiers, incidence rates, and time course) about impulse control disorders without support from the provided FDA label excerpts. While no direct contradictions are present, unsupported specificity could mislead clinical interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Impulse control disorder/boxed warning and quantitative risk statements are not supported by the supplied FDA label excerpts.
Suggested Improvement
Remove or qualify all impulse control disorder boxed-warning, incidence/rate, dose threshold, demographic, and mechanistic/genetic claims unless the corresponding FDA label sections (WARNINGS/BOXED WARNING, ADVERSE REACTIONS, and CLINICAL STUDIES) are provided and directly support the exact content.